The event: Phase III efficacy studies of Libigel for the treatment of female sexual dysfunction.
The timeline: Top-line results expected in the fall.
The stakes: A female Viagra, sort of. BioSante is trying to succeed where other drug companies have failed -- to be the first company to receive U.S. approval for a drug to boost the sexual "desire" of post-menopausal women. [Libigel is a low-dose testosterone gel that women apply once a day to their upper arm.]